Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $114,000.

  • 4D Molecular Therapeutics' Other Accumulated Expenses fell 13.60% to $108,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $108,000, marking a year-over-year decrease of 13.60%. This contributed to the annual value of $114,000 for FY2024, which is 9.62% up from last year.
  • 4D Molecular Therapeutics' Other Accumulated Expenses amounted to $114,000 in FY2024, which was up 9.62% from $104,000 recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Other Accumulated Expenses peaked at $1.8 million during FY2021, and registered a low of $104,000 during FY2023.
  • For the 3-year period, 4D Molecular Therapeutics' Other Accumulated Expenses averaged around $200,000, with its median value being $114,000 (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 260.49% in 2021, then tumbled by 78.42% in 2022.
  • 4D Molecular Therapeutics' Other Accumulated Expenses (Yearly) stood at $491,000 in 2020, then surged by 260.49% to $1.8 million in 2021, then crashed by 78.42% to $382,000 in 2022, then slumped by 72.77% to $104,000 in 2023, then increased by 9.62% to $114,000 in 2024.